This Article Full Text (PDF) All Versions of this Article: 1545109708322015v1 7/4/187    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Allavena, C. Articles by Raffi, F. Search for Related Content PubMed PubMed Citation Articles by Allavena, C. Articles by Raffi, F. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Impact of Education and Support on the Tolerability and Quality of Life in a Cohort of HIV-1 Infected Patients Treated With Enfuvirtide (SURCOUF Study)

Department of Infectiology, Hôtel Dieu, Nantes, clotilde.allavena{at}chu-nantes.fr

Thierry Prazuck, MD

Department of Infectiology, CHR Orléans

Véroniquer Reliquet, MD

Department of Infectiology, Hôtel Dieu, Nantes

Renaud Verdon, MD

Department of Infectiology, CHU Caen

Philippe Perré, MD

Department of Internal Medicine, CH La Roche sur Yon

Gwenael Le Moal, MD

Department of Infectiology, CHU Poitiers France

Eric Billaud, MD

Department of Infectiology, Hôtel Dieu, Nantes

François Raffi, MD

Department of Infectiology, Hôtel Dieu, Nantes

The aim of this study was to evaluate the quality of life and the intensity of the injection site reactions during the first 6 months of treatment with enfuvirtide according to the counseling and training provided by nurses and physicians. In this prospective, 6-month cohort, 61 HIV-1 infected adult patients starting enfuvirtide have been included. At baseline, 82% of the patients have either read information documents (23%) or received counseling (59%); 18% were self-injectors, 27.8% had a dual disposition (self-injector + third person), and 49.2% were injected by a third person. At month 6, among the 43 patients still on enfuvirtide, 59% have had no change in injection disposition, and 52% have the dual disposition. Quality of life and enfuvirtide acceptance improved during 6 months. With adequate education and choice of injection dispositions, treatment with enfuvirtide can lead to quality-of-life improvements.

Key Words: enfuvirtide • quality of life • antiretroviral therapy

This version was published on July 1, 2008

Journal of the International Association of Physicians in AIDS Care (JIAPAC), Vol. 7, No. 4, 187-192 (2008)
DOI: 10.1177/1545109708322015


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?